| 94 |
78: Reduction, Cumulative fecundity and spawning |
360: Decrease, Population growth rate |
Nov 29, 2016 |
Mar 20, 2017 |
12 AOPs
|
| 2142 |
78: Reduction, Cumulative fecundity and spawning |
361: Decline, Population |
May 25, 2020 |
May 25, 2020 |
None
|
| 2924 |
78: Reduction, Cumulative fecundity and spawning |
442: Decreased, Population trajectory |
May 22, 2023 |
May 22, 2023 |
2 AOPs
|
| 3228 |
1610: Reduction, DHEA |
1690: Decrease, circulating testosterone levels |
May 24, 2024 |
Apr 8, 2025 |
1 AOP
|
| 123 |
106: Reduction, Eggshell thickness |
253: N/A, Reproductive failure |
Nov 29, 2016 |
Dec 3, 2016 |
1 AOP
|
| 460 |
446: Reduction of testosterone |
414: Increase, Luteinizing hormone (LH) |
Nov 29, 2016 |
Dec 3, 2016 |
None
|
| 608 |
446: Reduction of testosterone |
348: Malformation, Male reproductive tract |
Nov 29, 2016 |
Dec 2, 2016 |
None
|
| 1649 |
446: Reduction of testosterone |
520: Decreased sperm quantity or quality in the adult, Decreased fertility |
Aug 11, 2017 |
Aug 11, 2017 |
None
|
| 143 |
129: Reduction, Gonadotropins, circulating concentrations |
274: Reduction, Testosterone synthesis by ovarian theca cells |
Nov 29, 2016 |
Mar 20, 2017 |
1 AOP
|
| 667 |
64: Reduction, Ionotropic GABA receptor chloride channel conductance |
669: Reduction, Neuronal synaptic inhibition |
Nov 29, 2016 |
Apr 29, 2019 |
1 AOP
|
| 683 |
669: Reduction, Neuronal synaptic inhibition |
682: Generation, Amplified excitatory postsynaptic potential (EPSP) |
Nov 29, 2016 |
May 15, 2018 |
1 AOP
|
| 1018 |
981: Reduction, NFAT/AP-1 complex formation |
982: Suppression, Suppression in mixed lymphocyte reaction (MLR) |
Nov 29, 2016 |
Dec 3, 2016 |
None
|
| 1019 |
981: Reduction, NFAT/AP-1 complex formation |
983: Suppression, Suppression of T-cell dependent antibody response (TDAR) |
Nov 29, 2016 |
Dec 3, 2016 |
None
|
| 1020 |
981: Reduction, NFAT/AP-1 complex formation |
984: Impairment, T-cell dependent antibody response |
Nov 29, 2016 |
Dec 3, 2016 |
None
|
| 1021 |
981: Reduction, NFAT/AP-1 complex formation |
985: Relief, Relief of atopic dermatitis |
Nov 29, 2016 |
Dec 3, 2016 |
None
|
| 1022 |
981: Reduction, NFAT/AP-1 complex formation |
986: Impairment of TDAR |
Nov 29, 2016 |
Dec 3, 2016 |
None
|
| 1256 |
981: Reduction, NFAT/AP-1 complex formation |
1203: Suppression, Suppression of production of cytotoxic T-cells |
Nov 29, 2016 |
Dec 3, 2016 |
None
|
| 1257 |
981: Reduction, NFAT/AP-1 complex formation |
1204: Suppression, Suppression of T-cell dependent antibody production |
Nov 29, 2016 |
Dec 3, 2016 |
None
|
| 1509 |
981: Reduction, NFAT/AP-1 complex formation |
1202: Suppression, IL-2 and IL-4 production |
May 19, 2017 |
Jun 27, 2021 |
1 AOP
|
| 252 |
219: Reduction, Plasma 17beta-estradiol concentrations |
285: Reduction, Vitellogenin synthesis in liver |
Nov 29, 2016 |
Mar 20, 2017 |
5 AOPs
|
| 253 |
219: Reduction, Plasma 17beta-estradiol concentrations |
309: Reduction, Vitellogenin accumulation into oocytes and oocyte growth/development |
Nov 29, 2016 |
Nov 29, 2016 |
None
|
| 392 |
219: Reduction, Plasma 17beta-estradiol concentrations |
405: disrupted, ovarian cycle |
Nov 29, 2016 |
Dec 3, 2016 |
1 AOP
|
| 1386 |
219: Reduction, Plasma 17beta-estradiol concentrations |
221: Reduction, Plasma vitellogenin concentrations |
Mar 17, 2017 |
Oct 18, 2018 |
7 AOPs
|
| 2922 |
219: Reduction, Plasma 17beta-estradiol concentrations |
2139: Reduction, the ratio of E2/11-KT in plasma |
May 22, 2023 |
May 22, 2023 |
1 AOP
|
| 255 |
221: Reduction, Plasma vitellogenin concentrations |
309: Reduction, Vitellogenin accumulation into oocytes and oocyte growth/development |
Nov 29, 2016 |
Mar 20, 2017 |
9 AOPs
|